15-Year watch begins for CAR T-Cell therapy recipients

NCT ID NCT06652633

Recruiting now Knowledge-focused Sponsor: Lakefront Biotherapeutics NV Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 14, 2026 · Updated 2 times

Summary

This study follows about 546 people who have already received a Galapagos CAR T-cell therapy for blood cancers. Researchers will check for long-term side effects and how well the treatment works over 15 years. No new treatment is given—just regular monitoring to meet safety guidelines for gene therapies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMATOLOGICAL MALIGNANCIES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEMATOLOGICAL MALIGNANCIES

Contacts and locations

Locations

Academisch Medisch Centrum (Amsterdam UMC)
RECRUITING

Amsterdam, 1105 AZ, Netherlands
Algemeen Ziekenhuis Delta
RECRUITING

Roeselare, 8800, Belgium
Antwerp University Hospital
RECRUITING

Edegem, 2650, Belgium
Centre Hospitalier Universitaire (CHU) De Liège
RECRUITING

Liège, 4032, Belgium
Cliniques Universitaires Saint-Luc
RECRUITING

Woluwe-Saint-Lambert, 1200, Belgium
Erasmus Medisch Centrum
RECRUITING

Rotterdam, 3015, Netherlands
Hospital Clinic De Barcelona
RECRUITING

Barcelona, 08036, Spain
Leids University Medical Center (LUMC)
RECRUITING

Leiden, 2333 ZA, Netherlands
Tufts Medical Center
RECRUITING

Boston, Massachusetts, 02111, United States
Universitair Ziekenhuis Leuven
RECRUITING

Leuven, 3000, Belgium
helsingin yliopistollinen sairaala comprehensive cancer center (HUS)
RECRUITING

Helsinki, 00290, Finland

More trials for these conditions

Other studies related to the condition(s) this trial covers.